MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, ARCT had -$19,391K decrease in cash & cash equivalents over the period. -$19,441K in free cash flow.

Cash Flow Overview

Change in Cash
-$19,391K
Free Cash flow
-$19,441K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Share-based compensation expense
    • Accounts receivable
    • Other
    • Others
Negative Cash Flow Breakdown
    • General and administrative
    • Accrued liabilities
    • Lease liabilities
    • Others

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Revenue
2,061 7,196 17,152 -
Total research and development
21,527 24,476 87,736 -
General and administrative
9,465 14,027 10,398 -
Other
-1,967 -2,228 -3,063 -
Net loss
-26,964 -29,079 -13,448 -23,256
Depreciation and amortization
658 682 763 1,580
Share-based compensation expense
4,325 6,817 5,729 12,862
Gain on sale of equipment
34 ---
Foreign currency transaction loss
-1 -63 -170 -149
Impairment of right-of-use assets
-1,897 --
Accounts receivable
-4,221 -2,387 -9,253 13,230
Prepaid expense and other assets
-809 -916 57 -4,145
Right-of-use assets
-658 -861 -955 -1,880
Accounts payable
-142 -1,343 -5,045 3,429
Accrued liabilities
-1,233 4,453 -5,417 -14,301
Deferred revenue
-636 -2,800 -8,986 -12,086
Lease liabilities
-1,104 -1,081 -1,068 -2,065
Net cash used in operating activities
-19,441 -16,227 -17,151 -40,893
Acquisition of property and equipment
0 -88 181 137
Proceeds from sale of equipment
34 ---
Proceeds from issuance of common stock under equity plans
-0 585 -
Net cash used in investing activities
34 88 -181 -137
Proceeds from issuance of common stock, net of issuance costs
-11,688 --
Payments on debt obligations
-0 0 15,000
Proceeds from exercise of stock options
16 0 640 469
Proceeds from debt
0 0 0 15,000
Net cash provided by financing activities
16 11,688 1,225 469
Net decrease in cash, cash equivalents and restricted cash
-19,391 -4,451 -16,107 -40,561
Cash, cash equivalents and restricted cash at beginning of the period
232,794 237,245 293,913 -
Cash, cash equivalents and restricted cash at end of the period
213,403 232,794 237,245 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from sale ofequipment$34K Proceeds from exercise ofstock options$16K Net cash used ininvesting activities$34K Net cash provided byfinancing activities$16K Net decrease incash, cash...-$19,391K Canceled cashflow$50K Share-based compensationexpense$4,325K Accounts receivable-$4,221K Prepaid expense andother assets-$809K Right-of-use assets-$658K Depreciation andamortization$658K Foreign currencytransaction loss-$1K Net cash used inoperating activities-$19,441K Canceled cashflow$10,672K Revenue$2,061K Other-$1,967K Net loss-$26,964K Canceled cashflow$4,028K Accrued liabilities-$1,233K Lease liabilities-$1,104K Deferred revenue-$636K Accounts payable-$142K Gain on sale ofequipment$34K Total research anddevelopment$21,527K General andadministrative$9,465K

Arcturus Therapeutics Holdings Inc. (ARCT)

Arcturus Therapeutics Holdings Inc. (ARCT)